MedTrace Logo

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

NCT01847222 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2015-01-06

No results posted yet for this study

Summary

Safety assessment of SANGUINATE™ in Healthy Volunteers.

Conditions

  • Drug Safety

Interventions

BIOLOGICAL

SANGUINATE™

PEG-bHb-CO

DRUG

Normal Saline Solution

Placebo

Sponsors & Collaborators

  • Prolong Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Benjamin Brenner, MD · Rambam Health Care Facility

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-05-31
Completion
2014-08-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01847222 on ClinicalTrials.gov